Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD.
Rusconi C, Barone A, Visentin A, Bianchi B, Zilioli VR, Bernardelli A, Iadecola S, Olivari E, Rossi FG, Gotti M, Cecchetti C, Puccini B, Franceschetti S, Molteni A, Steffanoni S, Marino F, Vanazzi A, Guidetti A, Merli M, Mazzon F, Marchetti A, Cellini A, Muzi C, Miceli R, Visco C, Re A, Corradini P.
Rusconi C, et al. Among authors: rossi fg.
Leuk Lymphoma. 2025 Jan 11:1-9. doi: 10.1080/10428194.2024.2446609. Online ahead of print.
Leuk Lymphoma. 2025.
PMID: 39797589